Skip to main content
. Author manuscript; available in PMC: 2023 Aug 14.
Published in final edited form as: Nat Rev Dis Primers. 2021 Dec 2;7(1):87. doi: 10.1038/s41572-021-00325-7

Figure 9. Treatment considerations in patients with refractory myositis based on the clinico-serologic presentation.

Figure 9.

Note: IVIg: Intravenous Immunoglobulins; ILD: Interstitial Lung Disease; DM: Dermatomyositis; JDM: Juvenile Dermatomyositis; Anti-SRP: Anti-Signal Recognition Particle; Anti-HMGCR: 3-hydroxy-3-methylglutaryl CoA reductase